Literature DB >> 26257863

Imaging in neuroendocrine tumors: an update for the clinician.

Jessica E Maxwell1, James R Howe1.   

Abstract

Neuroendocrine tumors are a heterogeneous group of neoplasms that are best worked up and managed using a variety of clinical and imaging studies. They are often diagnosed after they have already metastasized, though this does not necessarily preclude an attempt at curative surgical treatment or surgical debulking. Tumor burden assessment often requires use of multiple imaging modalities including computed tomography, magnetic resonance imaging and ultrasound. Somatostatin receptor-based imaging is also of great utility in looking for primaries and determining the extent of metastatic disease. This paper will review the most common imaging modalities used in the diagnosis and treatment of neuroendocrine tumors.

Entities:  

Keywords:  68Ga-DOTANOC; 68Ga-DOTATOC; CT; MRI; NET; OctreoScan; PET; neuroendocrine tumor; somatostatin imaging; ultrasound

Year:  2015        PMID: 26257863      PMCID: PMC4526141          DOI: 10.2217/ije.14.40

Source DB:  PubMed          Journal:  Int J Endocr Oncol        ISSN: 2045-0869


  52 in total

Review 1.  Principles of nuclear medicine imaging: planar, SPECT, PET, multi-modality, and autoradiography systems.

Authors:  Pat Zanzonico
Journal:  Radiat Res       Date:  2012-02-27       Impact factor: 2.841

Review 2.  ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.

Authors:  Valentina Ambrosini; Davide Campana; Paola Tomassetti; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

3.  68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.

Authors:  A Kroiss; D Putzer; C Decristoforo; C Uprimny; B Warwitz; B Nilica; M Gabriel; D Kendler; D Waitz; G Widmann; I J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-05       Impact factor: 9.236

Review 4.  Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours.

Authors:  Anders Sundin
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-12       Impact factor: 3.043

Review 5.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

Review 6.  Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.

Authors:  R J Hicks
Journal:  Cancer Imaging       Date:  2010-10-04       Impact factor: 3.909

7.  Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.

Authors:  Stefano Fanti; Valentina Ambrosini; Paola Tomassetti; Paolo Castellucci; Giancarlo Montini; Vincenzo Allegri; Gaia Grassetto; Domenico Rubello; Cristina Nanni; Roberto Franchi
Journal:  Biomed Pharmacother       Date:  2008-03-03       Impact factor: 6.529

8.  Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.

Authors:  E P Krenning; W H Bakker; P P Kooij; W A Breeman; H Y Oei; M de Jong; J C Reubi; T J Visser; C Bruns; D J Kwekkeboom
Journal:  J Nucl Med       Date:  1992-05       Impact factor: 10.057

9.  Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.

Authors:  A Chiti; S Fanti; G Savelli; A Romeo; B Bellanova; M Rodari; B J van Graafeiland; N Monetti; E Bombardieri
Journal:  Eur J Nucl Med       Date:  1998-10

10.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Authors:  I Buchmann; M Henze; S Engelbrecht; M Eisenhut; A Runz; M Schäfer; T Schilling; S Haufe; T Herrmann; U Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-23       Impact factor: 9.236

View more
  24 in total

Review 1.  Carcinoid Tumors: Past, Present, and Future.

Authors:  James R Howe
Journal:  Indian J Surg Oncol       Date:  2020-05-09

2.  Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model.

Authors:  Tania A Rozgaja Stallons; Amal Saidi; Izabela Tworowska; Ebrahim S Delpassand; Julien J Torgue
Journal:  Mol Cancer Ther       Date:  2019-03-29       Impact factor: 6.261

3.  Evaluation of a Neurokinin-1 Receptor-Targeted Technetium-99m Conjugate for Neuroendocrine Cancer Imaging.

Authors:  Ananda Kumar Kanduluru; Madduri Srinivasarao; Charity Wayua; Philip S Low
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

4.  Predictive Value of Asphericity in Pretherapeutic [111In]DTPA-Octreotide SPECT/CT for Response to Peptide Receptor Radionuclide Therapy with [177Lu]DOTATATE.

Authors:  Christoph Wetz; I Apostolova; I G Steffen; F Hofheinz; C Furth; D Kupitz; J Ruf; M Venerito; S Klose; Holger Amthauer
Journal:  Mol Imaging Biol       Date:  2017-06       Impact factor: 3.488

5.  Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Curr Probl Surg       Date:  2020-05-15       Impact factor: 1.909

6.  Radioligand Theranostics in the Management of Neuroendocrine Tumors.

Authors:  Alan G Harris; Aaron I Vinik; Thomas M OʼDorisio; M Sue OʼDorisio
Journal:  Pancreas       Date:  2020 May/Jun       Impact factor: 3.327

7.  THE ROLE OF TUMOR-SEEKING RADIOPHARMACEUTICALS IN THE DIAGNOSIS AND MANAGEMENT OF ADRENAL TUMORS.

Authors:  V Vukomanovic; M Matovic; A Djukic; V Ignjatovic; K Vuleta; S Djukic; I Simic Vukomanovic
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jul-Sep       Impact factor: 0.877

Review 8.  Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML).

Authors:  Rima Hajjo; Dima A Sabbah; Sanaa K Bardaweel; Alexander Tropsha
Journal:  Diagnostics (Basel)       Date:  2021-04-21

Review 9.  Management of Small Bowel Neuroendocrine Tumors.

Authors:  Aaron T Scott; James R Howe
Journal:  J Oncol Pract       Date:  2018-08       Impact factor: 3.714

10.  Metastatic primary testicular carcinoid tumor managed with radical orchiectomy, retroperitoneal lymph node dissection and inferior vena cava excision: Case report.

Authors:  H K Bangash; D Hayne; I A Thyer
Journal:  Urol Case Rep       Date:  2017-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.